Get the Stockscreener App
344.75
0.67%
-2.32
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $344.75, with a volume of 2.02M.
It is down -0.67% in the last 24 hours and up +4.00% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$347.07
Open:
$346.18
24h Volume:
2.02M
Relative Volume:
0.75
Market Cap:
$185.64B
Revenue:
$35.89B
Net Income/Loss:
$7.01B
P/E Ratio:
26.65
EPS:
12.9352
Net Cash Flow:
$11.54B
1W Performance:
+4.34%
1M Performance:
+4.00%
6M Performance:
+11.49%
1Y Performance:
+24.06%
1-Day Range:
$341.81
$349.23
1-Week Range:
$321.71
$349.98
52-Week Range:
$261.43
$349.98
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
344.75 | 186.89B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,064.29 | 973.23B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
220.14 | 526.41B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
219.26 | 385.48B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
147.14 | 278.22B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.26 | 276.52B | 46.69B | 15.29B | 9.25B | 3.4329 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Inc. $AMGN Shares Sold by Commerzbank Aktiengesellschaft FI - MarketBeat
Amgen Inc. $AMGN Shares Sold by AMF Tjanstepension AB - MarketBeat
Amgen stock pulled back after a six-day run — here’s what investors watch next week - TechStock²
Amgen (AMGN) Downgraded Amid Competitive Pressures and Uncertain Future - GuruFocus
Y Intercept Hong Kong Ltd Grows Position in Amgen Inc. $AMGN - MarketBeat
Mn Services Vermogensbeheer B.V. Purchases 3,900 Shares of Amgen Inc. $AMGN - MarketBeat
Resona Asset Management Co. Ltd. Lowers Stake in Amgen Inc. $AMGN - MarketBeat
UniSuper Management Pty Ltd Acquires 6,911 Shares of Amgen Inc. $AMGN - MarketBeat
Teacher Retirement System of Texas Decreases Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Strs Ohio - MarketBeat
Peering Into Amgen Inc's Recent Short Interest - Sahm
Assessing Amgen (AMGN) Valuation After The New Sagebrush 340B Lawsuit - simplywall.st
Amgen (AMGN) Faces Downgrade Amidst Promising Pipeline - GuruFocus
Amgen snaps after six straight sessions of gains - MSN
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock - Yahoo Finance
Lockheed Martin Investment Management Co. Makes New $2.62 Million Investment in Amgen Inc. $AMGN - MarketBeat
Analyst recommendations: Amgen, P&G, Spotify, Duolingo, Moderna… - marketscreener.com
Amgen (AMGN) Faces 340B Lawsuit: What Does Sagebrush Dispute Reveal About Its Stakeholder Strategy? - Yahoo Finance
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Amgen Faces 340B Lawsuit Spotlighting Drug Pricing And Investor Risks - simplywall.st
Amgen (AMGN) expands obesity strategy with Ro collaboration on GLP-1 therapies - MSN
Amgen (NASDAQ:AMGN) Hits New 1-Year HighHere's Why - MarketBeat
Amgen: A Buy In 2026 On Exciting MariTide ObesityT2D Potential (NASDAQ:AMGN) - Seeking Alpha
Amgen stock hits 52-week high at $346.41 - Investing.com
Sagebrush sues Amgen over 340B program row - The Pharma Letter
Rakuten Investment Management Inc. Purchases Shares of 27,258 Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Downgraded by Bernstein on Market Challenges - GuruFocus
Ember LifeSciences Taps Former Amgen Exec as CFO - Contract Pharma
Amgen downgraded at Bernstein on 2026 outlook - MSN
Cell and Gene Therapy Market Innovations and Key Players: Amgen - openPR.com
Johnson & Johnson Clears the Patent Cliff as 2026 Guidance Resets the Narrative - Investing.com
Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference - The AI Journal
Amgen (AMGN) Expands Obesity Strategy With Ro Collaboration on GLP-1 Therapies - Finviz
Amgen's (NASDAQ:AMGN) Shareholders Will Receive A Bigger Dividend Than Last Year - simplywall.st
Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.52 - Yahoo Finance
AMGEN INC (NASDAQ:AMGN) Shows High Technical and Setup Ratings for Potential Breakout - Chartmill
Arkadios Wealth Advisors Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN): Company Profile, Stock Price, News, Rankings - Fortune
Red Biotechnology Market Is Going to Boom 20262023 |Amgen Inc., Gilead Sciences, Inc., Biogen - openPR.com
UBS Raises PT on Amgen Inc. (AMGN) to $326 From $315, Keeps a Neutral Rating - MSN
Lobbying Update: $3,550,000 of AMGEN INC lobbying was just disclosed - Quiver Quantitative
Sagebrush Health Sues Amgen for Over $7 Million in Damages - Intellectia AI
Amgen (AMGN) Downgraded by Bernstein, Price Target Unchanged | A - GuruFocus
Bernstein downgrades Amgen as 2026 lacks near-term catalysts - Investing.com
Sanford C. Bernstein Downgrades Amgen (NASDAQ:AMGN) to Market Perform - MarketBeat
Seizert Capital Partners LLC Trims Stock Position in Amgen Inc. $AMGN - MarketBeat
Pacific Heights Asset Management LLC Has $23.99 Million Holdings in Amgen Inc. $AMGN - MarketBeat
UPS building massive $6 million cooler - The Business Journals
40 Under 40: Melissa Wagner, Amgen - Medical Marketing and Media
A Look At Amgen (AMGN) Valuation After Strong Q3 Results And Pipeline Momentum - Yahoo Finance
Amgen stock hits pause on MLK Day — what to watch before AMGN returns Tuesday - TechStock²
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.65%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):